新诺威：控股子公司SYS6090注射液获临床试验批准

Core Viewpoint - The announcement indicates that the subsidiary of the company, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SYS6090 injection, which will commence shortly [1] Group 1 - SYS6090 injection is a recombinant fully human anti-PD-1 fusion protein that incorporates IL-15, designed as an asymmetric structural bifunctional Fc [1] - The left arm of SYS6090 targets PD-1 positive tumor-infiltrating immune cells to block the immunosuppressive interaction between PD-1 and PD-L1 [1] - The right arm of SYS6090 binds to the IL-15 receptor, activating downstream signaling pathways to further promote the activation and proliferation of relevant immune cells [1]